Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 1
2007 2
2008 2
2009 2
2010 4
2011 4
2012 1
2013 5
2014 3
2015 9
2016 5
2017 4
2018 6
2019 4
2020 14
2021 12
2022 17
2023 21
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Carter K, Lippe R, Photowala H, Drogaris L, Soliman AM, Chen M, Padilla B, Behrens F. Kristensen LE, et al. Among authors: behrens f. Rheumatol Ther. 2024 Mar 18. doi: 10.1007/s40744-024-00654-5. Online ahead of print. Rheumatol Ther. 2024. PMID: 38498141 Free article.
ALISTER - Application for lipid stability evaluation and research.
Rischke S, Gurke R, Bennett A, Behrens F, Geisslinger G, Hahnefeld L. Rischke S, et al. Among authors: behrens f. Clin Chim Acta. 2024 Apr 15;557:117858. doi: 10.1016/j.cca.2024.117858. Epub 2024 Mar 15. Clin Chim Acta. 2024. PMID: 38492658 Free article.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
Coates LC, Landewé R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y, Asahina A, Behrens F, Gladman DD, Gossec L, Orbai AM, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Merola JF. Coates LC, et al. Among authors: behrens f. RMD Open. 2024 Feb 22;10(1):e003855. doi: 10.1136/rmdopen-2023-003855. RMD Open. 2024. PMID: 38388171 Free PMC article. Clinical Trial.
The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials.
Takase-Minegishi K, Böhringer S, Nam JL, Kaneko Y, Behrens F, Saevarsdottir S, Detert J, Leirisalo-Repo M, van der Heijde D, Landewé R, Ramiro S, van der Woude D. Takase-Minegishi K, et al. Among authors: behrens f. Rheumatology (Oxford). 2024 Feb 16:keae113. doi: 10.1093/rheumatology/keae113. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38366945
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V, Hueber AJ, Kleinert S, Baraliakos X, Braun J, Kiltz U, Fleck M, Rubbert-Roth A, Kofler DM, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Venhoff N, Thiel J, Glaser C, Feist E, Burmester GR, Karberg K, Strunk J, Cañete JD, Senolt L, Filkova M, Naredo E, Largo R, Krönke G, D'Agostino MA, Østergaard M, Schett G. Rech J, et al. Among authors: behrens f. Lancet. 2024 Mar 2;403(10429):850-859. doi: 10.1016/S0140-6736(23)02650-8. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364841 Clinical Trial.
Ixekizumab im Vergleich zu Fumarsäureestern und Methotrexat bei der Behandlung der Nagelpsoriasis bei Patienten mit mittelschwerer bis schwerer Psoriasis: Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis.
Augustin M, Mrowietz U, Willsmann-Theis D, Gerdes S, Fotiou K, Schuster C, Mert C, Holzkaemper T, Behrens F, Pinter A. Augustin M, et al. Among authors: behrens f. J Dtsch Dermatol Ges. 2024 Feb;22(2):278-282. doi: 10.1111/ddg.15292_g. J Dtsch Dermatol Ges. 2024. PMID: 38361190 No abstract available.
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F; MUST Investigator Group. Koehm M, et al. Among authors: behrens f. Lancet Rheumatol. 2023 Jan;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0. Lancet Rheumatol. 2023. PMID: 38251504 Clinical Trial.
115 results